Individualized therapy for metastatic colorectal cancer

Journal of Internal Medicine

Volumn 274, Issue 1, 2013, Pages 1-24

  Silvestri, A ^a   Pin, E ^a   Huijbers, A ^b   Pellicani, R ^a   Parasido, E M ^a   Pierobon, M ^c   Petricoin, E ^c   Liotta, L ^c   Belluco, C ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GEORGE MASON UNIVERSITY   (United States)

Author keywords

Colorectal cancer; Genomic profiling; Individualized therapy; Predictive biomarkers; Proteomic profiling

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SORAFENIB; UNTRANSLATED RNA;

ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; DNA METHYLATION; DNA REPLICATION; DRUG EFFICACY; EPIGENETICS; EXCISION REPAIR; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENOMICS; GENOTYPE; HUMAN; INDIVIDUALITY; INTRON; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; PROTO ONCOGENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMOGENIC COMPOUNDS; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; INDIVIDUALIZED MEDICINE; INTERDISCIPLINARY COMMUNICATION; LOSS OF HETEROZYGOSITY; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84879104939     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12070     Document Type: Article

References (154)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on day/month/year.
2. Koehler A, Bataille F, Schmid C et al. Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J Pathol 2004; 204: 65-74.
3. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-3.
4. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688-94.
5. Ries LAG, Melbert D, Krapcho M et al. (eds). SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
6. Cancer.net. Colorectal Cancer - Overview. Available at: http://www.cancer.net/patient/Cancer+Types/Colorectal+Cancer.In.
7. Sanoff HK, Sargent DJ, Campbell ME et al. N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC). J Clin Oncol (Meeting Abstracts) 2007; 25(18 suppl): 4067.
8. Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 2007; 13: 3806-15.
9. Adam R, Hoti E, Folprecht G, Benson AB. Accomplishments in 2008 in the management of curable metastatic colorectal cancer. Gastrointest Cancer Res 2009; 3: S15-22.
10. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247: 125-35.
11. Fiorentino F, Hunt I, Teoh K, Treasure T, Utley M. Pulmonary metastasectomy in colorectal cancer: a systematic review and quantitative synthesis. J R Soc Med 2010; 103: 60-6.
12. Bilchik AJ, Poston G, Adam R, Choti MA. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol 2008; 26: 5320-1.
13. Barone C, Nuzzo G, Cassano A et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 2007; 97: 1035-9.
14. Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-9.
15. Wang CC, Li J. An update on chemotherapy of colorectal liver metastases. World J Gastroenterol 2012; 18: 25-33.
16. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovirin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
17. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
18. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7.
19. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.
20. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-86.
21. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23: 9441-2.
22. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
23. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
24. Dotan E, Cohen SJ. Challenges in the management of stage II colon cancer. Semin Oncol 2011; 38: 511-20.
25. Kim ST, Lee J, Park SH et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010; 66: 659-67.
26. Zaanan A, Flejou JF, Emile JF et al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res 2011; 17: 7470-8.
27. Migliore L, Migheli F, Spisni R, Coppede F. Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol 2011; 2011: 792362.
28. Habermann JK, Paulsen U, Roblick UJ et al. Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosom Cancer 2007; 46: 10-26.
29. Postma C, Koopman M, Buffart TE et al. DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Ann Oncol 2009; 20: 1048-56.
30. Lee AJ, Endesfelder D, Rowan AJ et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011; 71: 1858-70.
31. Swanton C, Tomlinson I, Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 2006; 5: 818-23.
32. Mao X, Young BD, Lu YJ. The application of single nucleotide polymorphism microarrays in cancer research. Curr Genomics 2007; 8: 219-28.
33. Andersen CL, Wiuf C, Kruhoffer M, Korsgaard M, Laurberg S, Orntoft TF. Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis 2007; 28: 38-48.
34. Brenner BM, Rosenberg D. High-throughput SNP/CGH approaches for the analysis of genomic instability in colorectal cancer. Mutat Res 2010; 693: 46-52.
35. Melcher R, Al-Taie O, Kudlich T et al. SNP-array genotyping and spectral karyotyping reveal uniparental disomy as early mutational event in MSS- and MSI-colorectal cancer cell lines. Cytogenet Genome Res 2007; 118: 214-21.
36. Li YH, Wang F, Shen L et al. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients. Clin Cancer Res 2011; 17: 382-90.
37. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-93.
38. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-16.
39. Ang PW, Loh M, Liem N et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer 2010; 10: 227.
40. Hinoue T, Weisenberger DJ, Lange CP et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2011; 22: 271-82.
41. Jover R, Nguyen TP, Perez-Carbonell L et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011; 140: 1174-81.
42. Iacopetta B, Kawakami K, Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol 2008; 13: 498-503.
43. Shen L, Catalano PJ, Benson III AB, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007; 13: 6093-8.
44. Kawakami K, Matsunoki A, Kaneko M, Saito K, Watanabe G, Minamoto T. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci 2011; 102: 166-74.
45. Miyaki Y, Suzuki K, Koizumi K et al. Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer. Int J Oncol 2012; 40: 217-26.
46. Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 2004; 76: 528-35.
47. Cecchin E, Innocenti F, D'Andrea M et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27: 2457-65.
48. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99: 1290-5.
49. Cha PC, Mushiroda T, Zembutsu H et al. Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet 2009; 54: 572-80.
50. Di Martino MT, Arbitrio M, Leone E et al. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther 2011; 12: 780-7.
51. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275-80.
52. Stoehlmacher J, Park DJ, Zhang W et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936-42.
53. Stoehlmacher J, Ghaderi V, Iobal S et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001; 21: 3075-9.
54. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654-8.
55. Chen J, Xie F, Chen K et al. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Cancer Biol Ther 2009; 8: 1424-30.
56. Cho YB, Chung HJ, Lee WY et al. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. Anticancer Res 2011; 31: 3843-9.
57. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002; 8: 17-23.
58. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009; 158: 1-9.
59. Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 2010; 103: 1765-72.
60. Vecchione L, Jacobs B, Normanno N, Ciardiello F, Tejpar S. EGFR-targeted therapy. Exp Cell Res 2011; 317: 2765-71.
61. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007; 254: 165-77.
62. Takeuchi K, Ito F. EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J 2010; 277: 316-26.
63. Tsuchihashi Z, Khambata-Ford S, Hanna N, Janne PA. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 2005; 353: 208-9.
64. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351: 2883.
65. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
66. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-86.
67. Sartore-Bianchi A, Moroni M, Veronese S et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-45.
68. Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-21.
69. Moroni M, Sartore-Bianchi A, Veronese S, Siena S. EGFR FISH in colorectal cancer: what is the current reality? Lancet Oncol 2008; 9: 402-3.
70. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999; 274: 13176-80.
71. Graziano F, Ruzzo A, Loupakis F et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008; 26: 1427-34.
72. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-7.
73. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
74. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-5.
75. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
76. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-15.
77. Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-45.
78. Patil DT, Fraser CR, Plesec TP. KRAS testing and its importance in colorectal cancer. Curr Oncol Rep 2010; 12: 160-7.
79. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
80. Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC):OPUS, a randomized phase II study. J Clin Oncol 2007; 25: 4035.
81. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-705.
82. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-6.
83. Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-6.
84. Diaz LA Jr, Williams RT, Wu J et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-40.
85. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
86. Watanabe T, Kobunai T, Yamamoto Y et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 2011; 54: 1170-8.
87. Farber L, Efrati E, Elkin H et al. Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer. Virchows Arch 2011; 459: 487-93.
88. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010; 1805: 105-17.
89. Dibb NJ, Dilworth SM, Mol CD. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 2004; 4: 718-27.
90. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 2010; 127: 367-80.
91. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-12.
92. Rizzo S, Bronte G, Fanale D et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 2010; 36(Suppl 3): S56-61.
93. Cappuzzo F, Varella-Garcia M, Finocchiaro G et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008; 99: 83-9.
94. Jehan Z, Bavi P, Sultana M et al. Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol 2009; 219: 337-46.
95. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-24.
96. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005; 102: 802-7.
97. Ikenoue T, Kanai F, Hikiba Y et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005; 65: 4562-7.
98. Samuels Y, Diaz LA Jr, Schmidt-Kittler O et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7: 561-73.
99. Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69: 1851-7.
100. Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 2010; 29: 3033-4.
101. Perrone F, Lampis A, Orsenigo M et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20: 84-90.
102. Prenen H, De Schutter J, Jacobs B et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15: 3184-8.
103. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
104. Razis E, Briasoulis E, Vrettou E et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer 2008; 8: 234.
105. Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-30.
106. Koutras AK, Antonacopoulou AG, Eleftheraki AG et al. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J 2011; 12: 468-75.
107. Kim JC, Kim SY, Cho DH et al. Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. Clin Cancer Res 2011; 17: 1200-9.
108. Bitarte N, Bandres E, Boni V et al. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 2011; 29: 1661-7.
109. Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011; 71: 5214-24.
110. Ragusa M, Majorana A, Statello L et al. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 2010; 9: 3396-409.
111. Kohno K, Chiba M, Murata S et al. Identification of natural antisense transcripts involved in human colorectal cancer development. Int J Oncol 2010; 37: 1425-32.
112. Pierobon M, Calvert V, Belluco C et al. Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer 2009; 8: 110-7.
113. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007; 62: 179-213.
114. Giatromanolaki A, Sivridis E, Koukourakis MI. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 2006; 29: 408-17.
115. Giralt J, Navalpotro B, Hermosilla E et al. Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy. Oncology 2006; 71: 312-9.
116. Nozue M, Isaka N, Fukao K. Over-expression of vascular endothelial growth factor after preoperative radiation therapy for rectal cancer. Oncol Rep 2001; 8: 1247-9.
117. Zlobec I, Steele R, Compton CC. VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer 2005; 104: 2517-21.
118. Saltz LB, Meropol NJ, Loehrer PJS, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
119. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
120. Lax I, Bellot F, Howk R, Ullrich A, Givol D, Schlessinger J. Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules. EMBO J 1989; 8: 421-7.
121. King AC, Cuatrecasas P. Resolution of high and low affinity epidermal growth factor receptors. Inhibition of high affinity component by low temperature, cycloheximide, and phorbol esters. J Biol Chem 1982; 257: 3053-60.
122. Defize LH, Boonstra J, Meisenhelder J et al. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol 1989; 109: 2495-507.
123. Hebbar M, Wacrenier A, Desauw C et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006; 17: 855-7.
124. Kang MJ, Hong YS, Kim KP et al. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs 2011; 30: 1607-13.
125. Loupakis F, Pollina L, Stasi I et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 2622-9.
126. Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG. A robust automated measure of average antibody staining in immunohistochemistry images. J Histochem Cytochem 2009; 58: 95-107.
127. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
128. Espina V, Edmiston KH, Heiby M et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008; 7: 1998-2018.
129. Silvestri A, Colombatti A, Calvert VS et al. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest 2010; 90: 787-96.
130. Wulfkuhle JD, Speer R, Pierobon M et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008; 7: 1508-17.
131. VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin III EF. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn 2007; 7: 625-33.
132. Gallagher RI, Silvestri A, Petricoin III EF, Liotta LA, Espina V. Reverse phase protein microarrays: fluorometric and colorimetric detection. Methods Mol Biol 2011; 723: 275-301.
133. Grubb RL, Deng J, Pinto PA et al. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res 2009; 8: 3044-5.
134. Paweletz CP, Charboneau L, Bichsel VE et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981-9.
135. Silvestri A, Calvert V, Belluco C et al. Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. Clin Exp Metastasis 2013; 30: 309-16.
136. Belluco C, Mammano E, Petricoin E et al. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin Chim Acta 2005; 357: 180-3.
137. Perkins G, Lievre A, Ramacci C et al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Int J Cancer 2010; 127: 1321-3.
138. Chergui F, Chretien AS, Bouali S et al. Validation of a phosphoprotein array assay for characterization of human tyrosine kinase receptor downstream signaling in breast cancer. Clin Chem 2009; 55: 1327-36.
139. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005; 2: 416-22.
140. Chau GY, Lui WY, Chi CW et al. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection. Eur J Surg Oncol 2008; 34: 333-8.
141. Seidel C, Lenhoff S, Brabrand S et al. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 2002; 119: 672-6.
142. Pour L, Svachova H, Adam Z et al. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 2010; 57: 29-34.
143. Ishikawa N, Daigo Y, Takano A et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005; 65: 9176-84.
144. Kasahara K, Arao T, Sakai K et al. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin Cancer Res 2010; 16: 4616-24.
145. Racila E, Euhus D, Weiss AJ et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 1998; 95: 4589-94.
146. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-9.
147. Moreno JG, O'Hara SM, Gross S et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 2001; 58: 386-92.
148. Cohen SJ, Alpaugh RK, Gross S et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6: 125-32.
149. Cohen SJ, Punt CJ, Iannotti N et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 3213-21.
150. Cohen SJ, Punt CJ, Iannotti N et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 1223-9.
151. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-72.
152. Koopman M, Tol J, Miller MC et al. Circulating tumor cells (CTC) in advanced colorectal cancer (ACC) patients undergoing 1st line treatment with chemotherapy, bevacizumab and cetuximab as an important and early predictor of survival. Ann Oncol 2008; 19: viii166.
153. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol 2011; 9: 58-64.
154. Tursz T, Andre F, Lazar V, Lacroix L, Soria JC. Implications of personalized medicine-perspective from a cancer center. Nat Rev Clin Oncol 2011; 8: 177-83.